HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Altimmune (NASDAQ:ALT) and maintained a $12 price target.
May 14, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune's stock rating was reiterated as Buy by HC Wainwright & Co. with a maintained price target of $12.
Reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment and potentially drive the stock price up, especially when the price target suggests a significant upside.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100